Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Cue Biopharma, Inc. (CUE) had Stock-Based Compensation of $59.36M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$0.13M |
|
$-50.02M |
|
-- |
|
$0.13M |
|
$47.23M |
|
$-47.10M |
|
$-2.92M |
|
$-50.02M |
|
$-50.02M |
|
$-50.02M |
|
$-50.02M |
|
$-50.02M |
|
$-50.02M |
|
$-47.10M |
|
$-47.06M |
|
10.56M |
|
10.56M |
|
$-4.74 |
|
$-4.74 |
|
| Balance Sheet Financials | |
$66.71M |
|
$0.23M |
|
$0.55M |
|
$67.25M |
|
$19.73M |
|
-- |
|
$9.13M |
|
$28.86M |
|
$38.40M |
|
$38.40M |
|
$38.40M |
|
7.75M |
|
| Cash Flow Statement Financials | |
$-50.03M |
|
$-0.12M |
|
$80.95M |
|
$27.29M |
|
$58.09M |
|
$30.80M |
|
|
Stock-Based Compensation |
$59.36M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-35679.55% |
|
-35679.55% |
|
-- |
|
-37890.91% |
|
-37890.91% |
|
$-50.15M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.03 |
|
3499.09 |
|
-130.26% |
|
-130.26% |
|
-74.37% |
|
-130.26% |
|
$4.95 |
|
$-4.75 |
|
$-4.74 |
|